Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1584)
  2. Meeting Abstract (783)
  3. Book Section (104)
  4. Review (68)
  5. Editorial (58)
  6. Research Letter (42)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1668)
  2. Survivorship Research (1183)
  3. Solid Tumor Oncology Division (1037)
  4. Department of Pathology and Laboratory Medicine (947)
  5. Surgery (939)
  6. Melanoma and Immunotherapeutics Service (783)

More Groups

People
  1. Klaus Busam (689)
  2. Daniel Coit (542)
  3. Allan Halpern (396)
  4. Michael Postow (362)
  5. Alexander Shoushtari (244)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (56)
  2. 2024 (136)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (264)
  2. Annals of Surgical Oncology (220)
  3. Journal of the American Academy of Dermatology (122)
  4. Journal of Investigative Dermatology (80)
  5. Modern Pathology (66)
  6. International Journal of Radiation Oncology, Biology, Physics (64)

More Publications

Publishers
  1. Springer (340)
  2. American Society of Clinical Oncology (279)
  3. Elsevier Inc. (227)
  4. Lippincott Williams & Wilkins (226)
  5. Wiley Blackwell (160)
  6. American Association for Cancer Research (157)

More Publishers

Results (2735)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
    Meeting Abstract

    Smithy, J. W.; Kalvin, H. L.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib
    Meeting Abstract

    Chapman, P. B.; Klang, M.; Postow, M. A.; Shoushtari, A. N.; Sullivan, R. J.; Wolchok, J. D.; Wong, P.; Callahan, M. K.; Zippin, J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma
    Meeting Abstract

    Shoushtari, A. N.; Chaney, M. F.; Cohen, J. V.; Garyantes, T.; Lin, J. J.; Ishizuka, J. J.; Mita, A. C.; Mita, M. M.; Muller, C.; Natale, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Alden, S. L.; Smithy, J. W.; Ricciuti, B.; Alessi, J. V. M.; Wang, X.; Pecci, F.; Gandhi, M. M.; Lamberti, G.; Spurr, L. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression
    Meeting Abstract

    Pal, S. K.; Twardowski, P.; Chen, D. L.; Hall, E. T.; Hays, D.; Wilson, I.; Schmiedehausen, K.; Ferris, M.; Le, W.; Postow, M. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort
    Meeting Abstract

    Repetto, M.; Richards, A. L.; Chen, M. F.; Zhu, Y.; Selenica, P.; Gazzo, A.; Lee, P.; Price, A.; Yang, S. R.; Marra, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Meeting Abstract

    Barker, C. A.; D'Angelo, S. P.; Steckler, A. M.; Lian, M.; Wasilewski, G.; Lacouture, M. E.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Clonally expanded CD38(hi) cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
    Journal Article

    Wang, R.; Singaraju, A.; Marks, K. E.; Shakib, L.; Dunlap, G.; Adejoorin, I.; Greisen, S. R.; Chen, L.; Tirpack, A. K.; Aude, C.; more...
    Science Immunology (2023)

    Fulltext@MSK | Save